Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

122.72
+17.7816.94%
Post-market: 122.720.00000.00%19:30 EDT
Volume:510.62K
Turnover:60.10M
Market Cap:1.80B
PE:-13.82
High:126.50
Open:105.50
Low:104.71
Close:104.94
52wk High:155.29
52wk Low:24.27
Shares:14.67M
Float Shares:8.64M
Volume Ratio:1.63
T/O Rate:5.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-33.99
PE(LYR):-13.57

Loading ...

Inhibrx Biosciences Price Target Announced at $245.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 24

Inhibrx Biosciences, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $245

THOMSON REUTERS
·
Aug 24

Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus

Simply Wall St.
·
Aug 22

Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained

TIPRANKS
·
Aug 15

Inhibrx Falls on Wider-than-Expected Quarterly Loss

Reuters
·
Aug 14

Inhibrx Biosciences Q2 EPS $(2.34) Beats $(2.39) Estimate

Benzinga Earnings
·
Aug 14

Inhibrx Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

Inhibrx Net Loss Widens 27.9% to $36.7 Million in Q2 FY26; Revenue is no Revenue

Reuters
·
Aug 14

Inhibrx Q2 Operating Expenses USD 32.149 Million

THOMSON REUTERS
·
Aug 14

Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

Simply Wall St.
·
Jul 23

Inhibrx Shares Fall After Expanding Loan Agreement to $500M

Dow Jones
·
Jul 16

Inhibrx Biosciences Expands Oxford Finance Loan Facility to USD 500 Million

Reuters
·
Jul 16

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

THOMSON REUTERS
·
Jul 16

Inhibrx Biosciences - Second Amendment Adds up to $325 Mln, Including $100 Mln Funded and $225 Mln Available

THOMSON REUTERS
·
Jul 16

Inhibrx Biosciences (INBX) Following Russell Reshuffle With Valuation Still Hard To Pin Down

Simply Wall St.
·
Jul 08

Citizens healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 08

How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors

Simply Wall St.
·
Jul 03

Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?

Simply Wall St.
·
Jun 27

Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy

TIPRANKS
·
Jun 16